Express Scripts has opposed the price of Gilead Sciences’ Sovaldi treatment — $84,000 — since it was approved. The pharmacy benefits manager said that it was unaffordable. AbbVie’s Viekira Pak drug, recently approved by the U.S. Food and Drug Administration, has a significantly lower price, Express Scripts CMO Steve Miller.
More articles on gastroenterology:
Adopting the updated GI procedure quality metrics & what this means for practice
Making the most of 2015: New Year’s resolutions in GI
10 most-read GI/endoscopy stories of 2014
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
